Survival Prediction and Gene Identification with Penalized Global AUC Maximization

ZHENQIU LIU\textsuperscript{1}, RONALD B. GARTENHAUS,\textsuperscript{2} XUE-WEN CHEN,\textsuperscript{3} CHARLES D. HOWELL,\textsuperscript{2} and MING TAN\textsuperscript{1}

ABSTRACT

Identifying genes (biomarkers) and predicting the clinical outcomes with censored survival times are important for cancer prognosis and pathogenesis. In this article, we propose a novel method with $L_1$ penalized global AUC summary maximization ($L_1\text{GAUCS}$). The $L_1\text{GAUCS}$ method is developed for simultaneous gene (feature) selection and survival prediction. $L_1$ penalty shrinks coefficients and produces some coefficients that are exactly zero, and therefore selects a small subset of genes (features). It is a well-known fact that many genes are highly correlated in gene expression data and the highly correlated genes may function together. We, therefore, define a correlation measure to identify those genes such that their expression level may be low but they are highly correlated with the downstream highly expressed genes selected with $L_1\text{GAUCS}$. Partial pathways associated with the correlated genes are identified with DAVID (http://david.abcc.ncifcrf.gov/). Experimental results with chemotherapy and gene expression data demonstrate that the proposed procedures can be used for identifying important genes and pathways that are related to time to death due to cancer and for building a parsimonious model for predicting the survival of future patients. Software is available upon request from the first author.

Key words: biology, cancer genomics, combinatorial optimization, DNA arrays, functional genomics, gene clusters, gene expression, HMM, statistics.

1. INTRODUCTION

Because of the differences at molecular levels, patients may respond very differently to the same treatment. It is, therefore, very important to identify a small group of genes and pathways associated with survival. Gene selections with survival data in the statistical literature are mainly within the penalized Cox or additive risk regression framework (Tibshirani, 1996, 1998; Gui and Li, 2005; Van Houwelingen et al., 2006; Segal, 2006; Ma and Huang, 2007; Liu, 2007). The $L_1$ and $L_p$ ($p < 1$) penalized Cox regressions do

\textsuperscript{1}Division of Biostatistics, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland.
\textsuperscript{2}Department of Medicine and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
\textsuperscript{3}Bioinformatics and Computational Life Sciences Laboratory, Department of Electrical Engineering and Computer Science, University of Kansas, Lawrence, Kansas.
simultaneous gene (feature) selection and survival prediction, and have been extensively studied in the bioinformatics literature. Cox proportional hazards model is a semi-parametric model in which the baseline hazard is estimated nonparametrically, while the covariate (gene) effect is estimated by partial log likelihood maximization. The performance of the survival model is evaluated by the global area under the ROC curve summary (GAUCS) (Heagerty and Zheng, 2005).

The receiver operating characteristic (ROC) curve was originally proposed for evaluating the performance of binary classification (Bradley, 1997). An ROC curve provides complete information on the set of all possible combinations of true-positive and false-positive rates, but is also more generally useful as a graphic characterization of the magnitude of separation between the case and control distributions. AUC is known to measure the probability that the marker value (score) for a randomly selected case exceeds the marker value for a randomly selected control and is directly related to the Mann-Whitney U-statistic (Pepe, 2003, 2005). For survival data, a survival time can be viewed as a time-varying binary outcome. Given a fixed time for a randomly selected control and is directly related to the Mann-Whitney U-statistic (Heagerty and Zheng, 2005). Then, ROC curves are defined as

\[
\text{ROC}(t) = \frac{TP_t}{TP_t + FP_t}
\]

where TP. and FP. are the true and false positive rates at time t, respectively. The time-dependent sensitivity and specificity are defined by

\[
\text{sensitivity} = \frac{TP}{TP + FN}, \quad \text{specificity} = \frac{TN}{TN + FP}
\]

where TP, TN, FP, and FN are the numbers of true positives, true negatives, false positives, and false negatives, respectively.

It is a known fact that genes are highly correlated in gene expression data. However, standard statistical learning methods can only select a small subset of highly differentiated genes that lead to either the highest prediction accuracy or the smallest p-values, while most biologists recognize that the magnitude of differential expression does not necessarily indicate biological significance. From the biological perspective, even a very small change in expression of particular gene may have dramatic physiological consequences if the protein encoded by this gene plays a catalytic role in a specific cell function. Many other downstream genes may amplify the signal produced by this truly interesting gene, thereby increasing their chance to be selected by current gene selection methods. For a regulatory gene, however, the chance of being selected by current methods may diminish as these methods can only select downstream genes with bigger changes in expression. The characteristic of the regulatory genes is that their gene expression changes may be low, but they are highly correlated with the downstream highly expressed genes. We will catch those genes with our newly defined correlation measure.

This goal of the current study is to develop a computationally affordable and well-behaved estimating approach, which can effectively identify the genes for right censored survival data with \(L_1\) penalized GAUCS (L1GAUCS) maximization. In Section 2, we formulate the penalized GAUCS model and propose an efficient algorithm for simultaneous feature selection and survival prediction. The correlation measure for catching the upstream regularized genes is also introduced. The proposed approach is demonstrated with chemotherapy and gene expression examples in Section 3. Concluding remarks are discussed in Section 4.

2. \(L_1\) PENALIZED GLOBAL AUC SUMMARY MAXIMIZATION

Consider we have a set of \(n\) independent observations \(\{t_i, \delta_i, x_i\}_{i=1}^n\), where \(\delta_i\) is the censoring indicator and \(t_i\) is the survival time (event time) if \(\delta_i = 1\) or censoring time if \(\delta_i = 0\), and \(x_i = (x_{i1}, x_{i2}, \ldots, x_{im})^T\) is the m-dimensional input vector of ith sample. Let \(\beta = (\beta_1, \beta_2, \ldots, \beta_m)^T\) be a vector of regression coefficients, and we define \(M(x) = \beta^T x\) to be the risk score function, also denoting \(N_j^c(t) = 1_{(c \leq t)}\) and the corresponding increment \(dN_j^c(t) = N_j^c(t) - N_j^c(t-)\). The time-dependent sensitivity and specificity are defined by

\[
\text{sensitivity} = \frac{TP}{TP + FN}, \quad \text{specificity} = \frac{TN}{TN + FP}
\]

where TP, TN, FP, and FN are the numbers of true positives, true negatives, false positives, and false negatives, respectively. The characteristic of the regulatory genes is that their gene expression changes may be low, but they are highly correlated with the downstream highly expressed genes. We will catch those genes with our newly defined correlation measure.

This goal of the current study is to develop a computationally affordable and well-behaved estimating approach, which can effectively identify the genes for right censored survival data with \(L_1\) penalized GAUCS (L1GAUCS) maximization. In Section 2, we formulate the penalized GAUCS model and propose an efficient algorithm for simultaneous feature selection and survival prediction. The correlation measure for catching the upstream regularized genes is also introduced. The proposed approach is demonstrated with chemotherapy and gene expression examples in Section 3. Concluding remarks are discussed in Section 4.
[\{FP\}]^{-1}(p) = \inf \{ c : FP(c) \leq p \}. ROC methods can be used to characterize the ability of a marker to distinguish cases at time \( t \) from controls at time \( t \). However, in many applications there is identified no prior time \( t \), thus a global accuracy summary is defined by averaging over \( t \):

\[
\text{GAUCS} = 2 \int \text{AUC}(t)g(t)S(t) \, dt = \Pr (M_j > M_k | t_j < t_k),
\]

which indicates the probability that the subject who died (cases) at the early time has a larger value of the marker, where \( S(t) \) and \( g(t) \) are the survival and corresponding density functions, respectively.

We can define the optimization problem

\[
\max \, \text{GAUCS} = \max \, \Pr (M_j > M_k | t_j < t_k) \quad \text{s.t.} \quad |\beta| < \gamma,
\]

where \( M_j = \beta^T x_j \) and \( |\beta| = L_1 = \sum_{j=1}^{m} |\beta_j| \). The ideal situation is that \( M(x_j) > M(x_k) \) or \( \beta^T (x_j - x_k) > 0, \forall \) couple \((x_j, x_k)\) with corresponding times \( t_j < t_k \) (or \( j < k \)) and \( \delta_j = 1 \). If we allow margins between couples \((x_j, x_k)\) for all \( j < k \) and take a quadratic loss function, the optimization problem can be defined as

\[
\min \frac{1}{2N} \sum_{j' = 1}^{n} \sum_{k = 2}^{n} \hat{\epsilon}_{jk}^2 + \lambda |\beta| \quad \text{s.t.} \quad \beta^T (x_j - x_k) \geq 1 - \hat{\epsilon}_{jk}, \quad \hat{\epsilon}_{jk} \geq 0, \forall 1 < k \leq n,
\]

where \( N = \sum_{j'=1}^{j<k} 1 \) is the number of items with \( j < k \) and \( \delta_j = 1 \). When ties in the event times are presented, variables associated with each tied time appear in the constraints independently. Solving equation (2) is equivalent to solving the following problem:

\[
\min J(\beta; \hat{\epsilon}) = \frac{1}{2N} \sum_{j'=1}^{j<k} \sum_{k = 2}^{n} (1 - \beta^T (x_j - x_k))^2 + \lambda |\beta|,
\]

where \( Z_+ \) is \( Z \) if \( Z > 0 \), and 0 otherwise. Note that \( |\beta| \) is not differentiated at 0, we therefore introduce the subdifferential concept (Hiriart-Urruty and Lemaréchal, 2001) for the derivatives. The subdifferential of a convex function \( f(\beta) \) is defined as

\[
\partial f(\beta) = \{ s | f(\beta + \Delta) > f(\beta) + s\Delta, \forall \Delta \in R \}.
\]

In other words, a subdifferential is a range of slopes \( s \) such that the line through \((\beta, f(\beta))\) with slope \( s \) contains the graph of \( f \) in its upper half space. This is a set-valued generalization of the normal derivative and reduce to the normal derivative \( \partial f(\beta) = \{ \nabla f(\beta) \} \). \( \beta \) is a global minimizer of a convex function \( f(\beta) \) if and only if \( 0 \in \partial f(\beta) \).

To find the optimal solution of \( \beta \), we first rewrite the first part \( J(\beta; 0) \) of equation (3) as a function of the \( i \)-th parameter \( \beta_i \) and treat remaining parameters \( \beta_{-i} \) as fixed constants.

Let \( I(x_j, x_k) = \begin{cases} 1, & \text{if } 1 - \beta_i^T (x_j - x_k) > 0, \\ 0, & \text{otherwise} \end{cases} \) we have

\[
J(\beta_i; 0) = \frac{1}{2N} \sum_{j'=1}^{j<k} \sum_{k = 2}^{n} (1 - \beta^T (x_j - x_k))^2 \cdot I(x_j, x_k)
\]

\[
= \frac{1}{2N} \sum_{j'=1}^{j<k} \sum_{k = 2}^{n} (1 - \beta_{-i}^T (x_j - x_k) - \beta_i(x_{ji} - x_{ki}))^2 \cdot I(x_j, x_k)
\]

\[
= \frac{1}{2N} \sum_{j'=1}^{j<k} \sum_{k = 2}^{n} (1 - \beta_{-i}^T (x_j - x_k) - \beta_i(x_{ji} - x_{ki}))^2 I(x_j, x_k)
\]

\[
= \frac{1}{2} b_i \beta_i^2 + c_i \beta_i + d_i,
\]
where

\[ b_i = \frac{1}{N} \sum_{j \neq i} \sum_{k=2}^{n} (x_{ij} - x_{ik})^2 I(x_j, x_k), \]

\[ c_i = \frac{1}{N} \sum_{j \neq i} \sum_{k=2}^{n} (x_{ij} - x_{ik})(1 - \beta^T(y_j - x_k)_-)I(x_j, x_k), \]

\[ d_i = \frac{1}{2N} \sum_{j \neq i} \sum_{k=2}^{n} (1 - \beta^T(y_j - x_k)_-)I(x_j, x_k). \]

Equation (5) is a quadratic function of \( \beta_i \), the first order derivative w.r.t. \( \beta_i \) is

\[ \frac{\partial J(\beta; 0)}{\partial \beta_i} = b_i \beta_i + c_i. \]

Then the subdifferential of \( J(\beta; \lambda) \) w.r.t. \( \beta_i \) is

\[ \partial_{\beta_i} J(\beta; \lambda) = \partial_{\beta_i} J(\beta; 0) + \lambda \partial_{\beta_i} |\beta| = \frac{\partial J(\beta; 0)}{\partial \beta_i} + \lambda \partial_{\beta_i} |\beta|. \]  

(6)

According to equation (4), the subdifferential of the \( L_1 \) penalty is

\[ \partial_{\beta_i} |\beta| = \begin{cases} 
-1, & \beta_i < 0, \\
-1, +1, & \beta_i = 0, \\
+1, & \beta_i > 0.
\end{cases} \]

We have

\[ \partial_{\beta_i} J(\beta; \lambda) = \begin{cases} 
(b_i \beta_i - c_i - \lambda), & \beta_i < 0 \\
-c_i - \lambda, -c_i + \lambda, & \beta_i = 0 \\
(b_i \beta_i - c_i + \lambda), & \beta_i > 0
\end{cases}. \]

(7)

The subdifferential \( \partial_{\beta_i} (\beta; \lambda) \) is a piece-wise monotonically increasing linear function with the slope \( b_i > 0 \). To find the global minimum, we set \( J_{\beta_i}(\beta; \lambda) = 0 \). The value of \( c_i \) (relative to \( \lambda \)) controls which part of \( J_{\beta_i}(\beta; \lambda) \) is set to zero. (1) if \( c_i < -\lambda \), then \( -c_i - \lambda > 0 \), so that \( \beta_i < 0 \) for the zero-intercept. Solving \( b_i \beta_i - c_i + \lambda = 0 \), we have \( \beta_i = \frac{c_i + \lambda}{b_i} < 0 \). (2) if \( c_i \in [ -\lambda, \lambda] \), then \( -c_i - \lambda \leq 0 \leq -c_i + \lambda \), or \( 0 \in [ -c_i - \lambda, -c_i + \lambda] \). Hence, the global minimum occurs at \( \beta_i = 0 \). (3) if \( c_i > \lambda \), then \( -c_i + \lambda < 0 \), so that the zero intercept is greater than zero, we set \( b_i \beta_i - c_i + \lambda = 0 \), the global minimum. We have \( \beta_i = \frac{c_i + \lambda}{b_i} > 0 \). Putting these results together, the optimal solution \( \hat{\beta}_i \) is a piece-wise linear, monotonically increasing function of \( c_i \):

\[ \hat{\beta}_i(c_i) = \begin{cases} 
(c_i + \lambda) / b_i, & c_i < -\lambda \\
0, & c_i \in [ -\lambda, +\lambda] \\
(c_i - \lambda) / b_i, & c_i > +\lambda.
\end{cases} \]

(8)

Therefore, we can update the coefficient of each input with fixed left coefficients. The coordinator-wised algorithm is very easy to implement and converges in \( O(mN) \).

In gene expression analysis, after we select a small subset of downstream genes with bigger change in expression, we will identify those regularized genes that may have low expression but are highly correlated with each of the highly expressed genes using a newly defined correlation measure \( R \). \( R(x, y) = \frac{\text{cov}(x, y)}{\text{min} \left( \text{var}(x), \text{var}(y) \right)} \), where \( \text{cov}(x, y) = \sum (x_i - \bar{x})(y_j - \bar{y})^T \) is the standard covariance and \( \text{var}(x) = \sum (x_i - \bar{x})^2 \) is the variance. Based on this definition, we have \( R(x, y) = R(y, x) \), and \( R = 0 \) when \( x \) and \( y \) are independent. This \( R \) is different from the standard correlation coefficient \( r = \text{cov}(x, y) / \sqrt{\text{var}(x) \cdot \text{var}(y)} \) in its denominator. It can catch the genes that have very small change in expression but are highly correlated with significant expressed (downstream) genes. For instance, given \( \text{cov}(x, y) = 0.01 \), \( \text{var}(x) = 0.01 \), and \( \text{var}(y) = 1 \), we have \( R = 1 \) but \( r = 0.1 \). Therefore, we can identify several highly correlated gene clusters with \( R \) and find the related partial pathways associated with these gene clusters using DAVID (http://david.abcc.ncifcrf.gov/).
3. COMPUTATIONAL RESULTS

3.1. Breast cancer prognosis and chemotherapy data

Our first example is a publicly available data with 253 breast cancer patients (Wolberg et al., 1999). The data set contains patients’ 32 nuclear features, survival time, and chemotherapy information. The 32 features include the mean, standard deviation, and maximum (worst) values of ten cytological nuclear measurement of size, shape, and texture taken from the patient’s breast by a non-surgical fine needle aspirate procedure, together with the tumor size excised from the patient’s breast during surgery and lymph node metastasis. We want to identify a subsect of features that can predict the survival of the patients. Ten-fold cross-validations are used to evaluate the performance of the proposed method. To prevent the bias coming from a specific partition, we divide the data into ten-folds 100 times and overall performance of the model is evaluated. The optimal path of the coefficient estimate and the average test GAUCS with different $\lambda$ are given in Figures 1 and 2, respectively. Figures 1 and 2 show that the proposed method reaches maximal global AUC summary at $\lambda^* = 0.2$ and all $\beta_i$’s are zero, when $\lambda = 0.9$. The selected features with $\lambda^* = 0.2$ and the comparison of the proposed methods and penalized Cox regression $L_1$COX (Gui and Li, 2005) are given in Table 1. Table 1 shows that lymph node status, tumor size, and the largest perimeter are strongly associated with death. The larger those three variables, the later the breast cancer stage and, therefore, the less the survival time. This is consistent with common sense. Other nuclear features selected with $L_1$GAUCS and $L_1$COX methods are not totally consistent, but most of them are either the same or related. The performance comparison with 100 partitions is given in Figure 3. $L_1$GAUCS performs statistically significant better than $L_1$COX methods with two more features. The optimal $\lambda^* = 0.2$ and average test $GAUCS = 0.8$ with $L_1$GAUCS, and the optimal $\lambda^* = 4.5$ and the average test $GAUCS = 0.77$ with $L_1$COX method.

3.2. MCL microarray data

A survival study for mantle cell lymphoma (MCL) patients with gene expression data was reported by Rosenwald et al. (2003). The primary goal of this study was to discover genes that have good power to predict the patients’ survival risk. Among 101 untreated patients with no history of previous lymphoma included in this study, 92 were classified as having MCL based on established morphologic and immunophenotypic criteria. Survival times of 64 patients were available, and the other 28 patients were censored. The median survival time was 2.8 years (range, 0.02–14.05 years). Lymphochip DNA microarrays were used to quantify mRNA expressions in the lymphoma samples from the 92 patients. The gene expression data contains expression values of 8810 genes. Utilizing a two-step approach, we first built marginal $L_1$GAUCS models with the expression levels for each gene as a one-dimensional input. All genes with marginal $p$-values less than 0.1 are then included in the second step $L_1$GAUCS survival model. Similar approach has been extensively used in previous studies (Ma and Huang, 2007). Out of 8810 genes, 1721 are identified to be marginally significant at the 0.1 level. We then build a $L_1$GAUCS model with the 1721

![FIG. 1. Optimal path of the coefficients.](attachment:image.png)
genes. $L_1$ GAUCS includes a regularization parameter, controlling the complexity of the model and the sparsity of the model parameters, which must be chosen by the user or alternatively optimized in an additional model selection stage. However, we cannot use the same cross-validation estimate for both model selection and performance evaluation, as this would introduce a strong selection bias in favor of the existing $L_1$ GAUCS model. A nested cross-validation procedure is therefore used instead. Ten-fold cross-validation is used for performance evaluation in the “outer loop” of the procedure, in each iteration of which model selection is performed individually for each classifier based on a separate leave-one-out cross-validation procedure using the training data only. Because of the small sample size and high-dimensional genes, leave-one-out cross-validation in the “inner loop” is likely to provide a reliable performance measure for model selection. Even though this nested cross-validation is computationally expensive, it provides an almost unbiased assessment of generalization performance as well as a sensible automatic method of setting the value of the regularization parameter. The optimal regularized parameter is $\lambda = 0.3$, and the average test GAUCS = 0.84 with only six genes with nonzero estimates. Genes selected with the $L_1$ GAUCS survival prediction method are listed in Table 2.

The description of the six genes can be found at the NCBI website (www.ncbi.nlm.nih.gov). Gene Hs.497741 (CENPF) encodes a protein associated with the centromere-kinetochore complex, 3210 amino acids (aa), 367594 Da, containing internal repeats, coiled-coil (potential) and NLS (potential). Overexpression of CENPF mRNA was associated with larger tumor size as well as estrogen receptor (ER)–negative, high-grade tumors. CENPF mRNA expression correlated significantly with worse overall survival and a decreased probability of remaining metastasis-free, which may indicate that CENPF itself is a good candidate for biomarker for MCL. Studies show that gene Hs.156346 (TOP2A) is a proliferation marker, an indicator of drug sensitivity, and a prognostic factor in mantle cell lymphoma. This gene encodes a DNA

![Average test GAUCS with different lambda values.](image)

### Table 1. Selected Features with Different Survival Model

<table>
<thead>
<tr>
<th>Features</th>
<th>$L_1$ GAUCS Estimators</th>
<th>$L_1$ COX Estimators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Texture</td>
<td>-0.191</td>
<td>Perimeter</td>
</tr>
<tr>
<td>Concave point</td>
<td>-0.079</td>
<td>Symmetry</td>
</tr>
<tr>
<td>SD compactness</td>
<td>0.083</td>
<td>Fractal dimension</td>
</tr>
<tr>
<td>Largest perimeter</td>
<td>0.316</td>
<td>SD radius</td>
</tr>
<tr>
<td>Tumor size</td>
<td>0.168</td>
<td>Tumor size</td>
</tr>
<tr>
<td>Lymph node status</td>
<td>0.134</td>
<td>Lymph node status</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Worst smoothness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Worst concavity</td>
</tr>
</tbody>
</table>

$\lambda^* = 0.2$ $GAUCS = 0.80$ $\lambda^* = 4.5$ $GAUCS = 0.774$
topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. The gene encoding this enzyme functions as the target for several anticancer agents, and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. Gene Hs.241517 (DNA Pol theta) has a specialized function in lymphocytes and in tumor progression. Three other genes (Hs.532755, Hs.142442, and Hs.521101) are also either directly associated with lymphoma or important in tumor proliferation.

We then identify the highly correlated genes with $|R| > 0.9$ for each of the six selected genes and find the associated partial pathways for the highly correlated genes with DAVID. The associated pathways are given in Table 3. Pathways identified in Table 3 play a crucial role in regulating the growth and survival of MCL. For instance, TGF-beta signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis, and other cellular functions. Studies (Moller et al., 2007) showed that upregulation of the TGFbeta signaling pathway has implications for hemopoietic cell growth and chronic myeloid leukemia. P53 signaling is another well-known cancer-related pathway. The tumor-suppressor protein p53 exhibits sequence-specific DNA-binding, directly interacts with various cellular and viral proteins, and induces cell cycle arrest in response to DNA damage. The p53-dependent pathways help to maintain genomic stability by eliminating damaged cells either by arresting them permanently or through apoptosis. p53, therefore, is frequently targeted by genetic alterations in MCL patients. Most other survival-related pathways identified are also related to either the cell cycle machinery and senescence, DNA damage response pathways, or cell survival signals. In this article, we discuss cell cycle and MCL in more detail.

KEGG cell cycle regulatory pathway and associated correlated genes are given in Figure 4 and Table 4, respectively. Regulation of the cell cycle involves steps crucial to the cell, including detecting and repairing genetic damage, and provision of various checks to prevent uncontrolled cell division. Thirteen genes identified on the pathway are over-expressed for patients with less survival time. All 13 genes are important in cell cycle regulation in MCL. Both Cyclin D1 (CCND1) and cyclin b1 are the key regulators of the cell cycle and are overexpressed in patients with a shorter survival time. Elevated levels of CCND1 expression in MCL cells may accelerate G1/S-phase transition of the cell and therefore tumor cell proliferation. Many studies suggest that CCND1 deregulation plays an important role in pathogenesis of MCL, and the level CCND1

---

**Table 2. Selected Genes with Nonzero Estimates**

<table>
<thead>
<tr>
<th>UniGene ID</th>
<th>Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hs.497741</td>
<td>Centromere protein F, 350/400 kDa (mitosin)</td>
</tr>
<tr>
<td>Hs.156346</td>
<td>Topoisomerase (DNA) II alpha 170 kDa</td>
</tr>
<tr>
<td>Hs.532755</td>
<td>Likely ortholog of mouse gene trap locus 3</td>
</tr>
<tr>
<td>Hs.241517</td>
<td>Polymerase (DNA directed), theta</td>
</tr>
<tr>
<td>Hs.142442</td>
<td>HP1-BP74</td>
</tr>
<tr>
<td>Hs.521101</td>
<td>Similar to Williams-Beuren syndrome critical region protein 19</td>
</tr>
</tbody>
</table>
### Table 3. Survival-Related Pathways for Correlated Genes

<table>
<thead>
<tr>
<th>UniGene ID</th>
<th>Associated KEGG pathways</th>
</tr>
</thead>
</table>
| Hs.497741(314) | Cell cycle (13)  
|             | TGF-beta signaling pathway (6)  
|             | Ubiquitin mediated proteolysis (7)  
|             | p53 signaling pathway (5)  
|             | One carbon pool by folate (5)  |
| Hs.156346 (228) | Wnt signaling pathway (12)  
|             | Purine metabolism (11)  
|             | MAPK signaling pathway (15)  
|             | Apoptosis (8)  
|             | Insulin signaling pathway (10)  
|             | Cell cycle (14)  |
| Hs.532755 (270) | Cell cycle (12)  
|             | TGF-beta signaling pathway (6)  
|             | p53 signaling pathway (5)  
|             | Adherens junction (5)  
|             | Tight junction (5)  |
| Hs.241517 (89) | Cell cycle (5)  
|             | p53 signaling pathway (3)  |
| Hs.142442 (34) | Pathogenic *Escherichia coli* infection—EPEC (2)  
|             | Pathogenic *Escherichia coli* infection—EHEC (2)  |
| Hs.521101 (1)  | None |

![FIG. 4. KEGG pathway: cell cycle.](image-url)
expression appears to be directly correlated with the tumor cell proliferation rate in MCL. Both CDK1 (CDC2) and CDK2 are overexpressed in patients with a shorter survival time. They are the members of a large family of protein kinases that initiate the principal transitions of the eukaryotic cell cycle. Mutations in the CDKs and/or their inhibitors is associated with several forms of cancer. CDKs perform a common biochemical reaction, called “phosphorylation,” that activates or inactivates target proteins to orchestrate coordinated entry into the next phase of the cell cycle. The interaction of cyclins (b1, d1) and CDKs determines a cell’s progress through the cell cycle. Polo-like kinases (Plks) are important regulators of cell cycle progression during M-phase. Plks are involved in the assembly and dynamics of the mitotic spindle apparatus and in the activation and inactivation of CDK/cyclin complexes. Plk1 has a role in the regulation of tyrosine dephosphorylation of CDKs through phosphorylation and activation of Cdc25C. Other genes identified also play very important roles in cell cycle. Many pharmacologic strategies targeting cell-cycle regulatory pathways have been proposed. Cyclin D1, CDKs, Plks, and other genes are all potential cancer drug targets.

4. CONCLUSION

It is of great interest to develop sound computational techniques that are capable of both identifying disease-associated genes and related pathways, and predicting survival risks based on the selected genes. In this article, we have developed $L_1$ penalized global AUC summary ($L_1$GAUCS) maximization methods for gene (feature) selection, pathway identification, and survival prediction with right censored survival data and high-dimensional gene expression profiles. This is the first attempt to use the penalized global AUC maximization for survival analysis. We analyze the chemotherapy and MCL microarray data using the proposed approach. Empirical studies have showed that the proposed approach is able to identify the small subset of genes (features) with nice prediction performance.

Furthermore, it is well known that many genes are highly correlated in gene expression data. The standard supervised learning methods can only identify a small subset of independent genes with the highest prediction power. We have defined a novel correlation measure to identify those highly correlated genes. Most pathways and related genes we find have been shown to be associated with MCL in other studies.

We have found hundreds (or tens) of genes associated with each gene identified with $L_1$GAUCS. Only a small number of genes are appeared on the partially known pathway. Other genes are left unexplored. We will explore the gene-gene interaction and causal relation among the correlated genes in a separate study.

ACKNOWLEDGMENTS

We thank the associate editors and the anonymous referees for their constructive comments which helped improve the manuscript. Z. Liu was partially supported by grant 1R03CA128102-02 from the National Institute of Health. X. Chen was partly supported by NSF-0644366 CAREER award.
DISCLOSURE STATEMENT

No competing financial interests exist.

REFERENCES


Address correspondence to:
Dr. Zhenqiu Liu
Division of Biostatistics
Greenebaum Cancer Center
University of Maryland Baltimore
685 West Baltimore Street, Suite 261
Baltimore, MD 21201

E-mail: zliu@ummb.edu